Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Kim, Joon Hyung, Levin, Myron J., Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733973/
https://www.ncbi.nlm.nih.gov/pubmed/32347767
http://dx.doi.org/10.1080/21645515.2020.1741312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733973/
https://www.ncbi.nlm.nih.gov/pubmed/32347767
http://dx.doi.org/10.1080/21645515.2020.1741312

Ejemplares similares